Best of TTLC 2024

Overview

Key points of this webinar encompass significant research findings presented at the recent Targeted Therapies in Lung Cancer (TTLC) conference held in Santa Monica, CA. The landscape of lung cancer therapy is swiftly advancing with the introduction of numerous novel drugs and treatment approaches in the past year. With emerging evidence, there exist opportunities to enhance patient outcomes, and we aim to facilitate the dissemination of this knowledge to our audience for the integration of these innovative practices.

CME Accredited

At the end of the webinar, learners will be able to:
Accreditation Council for Continuing Medical Education (ACCME)

Explain optimal treatment recommendations and indications for patients with EGFR-mutated NSCLC
Identify optimal perioperative treatments for patients with early-stage NSCLC
Summarize the role for novel therapies in metastatic lung cancer.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.

The International Association for the Study of Lung Cancer designates the live format for this educational activity for a maximum of 1.00 AMA PRA Category 1 Credits. Physicians should only claim credit commensurate with the extent of their participation in the activity.

At the end of the webinar, learners will be able to:

Explain optimal treatment recommendations and indications for patients with EGFR-mutated NSCLC
Identify optimal perioperative treatments for patients with early-stage NSCLC
Summarize the role for novel therapies in metastatic lung cancer.

Accreditation Council for Continuing Medical Education (ACCME)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.

The International Association for the Study of Lung Cancer designates the live format for this educational activity for a maximum of 1.00 AMA PRA Category 1 Credits. Physicians should only claim credit commensurate with the extent of their participation in the activity.